{"id":"folfox-7","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Bevacizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Cyclosporine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Fentanyl","action":"Monitor","effect":"Increased risk of respiratory depression"},{"drug":"Leucovorin","action":"Monitor","effect":"Increased risk of toxicity"},{"drug":"Oxaliplatin","action":"Monitor","effect":"Increased risk of neurotoxicity"},{"drug":"Pemetrexed","action":"Monitor","effect":"Increased risk of toxicity"},{"drug":"Pentobarbital","action":"Monitor","effect":"Increased risk of central nervous system depression"},{"drug":"Phenytoin","action":"Monitor","effect":"Increased risk of toxicity"},{"drug":"Ranitidine","action":"Monitor","effect":"Increased risk of toxicity"},{"drug":"Sulindac","action":"Monitor","effect":"Increased risk of toxicity"},{"drug":"Temozolomide","action":"Monitor","effect":"Increased risk of toxicity"},{"drug":"Thiopental","action":"Monitor","effect":"Increased risk of central nervous system depression"},{"drug":"Vincristine","action":"Monitor","effect":"Increased risk of neurotoxicity"}],"commonSideEffects":[],"contraindications":["Oxaliplatin is contraindicated in patients who have/are: * Platinum hypersensitivity anaphylaxis * Posterior reversible encephalopathy syndrome * Grade 3 or 4 peripheral sensory neuropathy * Severe renal impairment * Chronic lung disease * Rhabdomyolysis * Sepsis * Pregnant or intending to get pregnant * Breastfeeding Use in the first trimester should be avoided due to high teratogenicity and embryo or fetal death. Females of reproductive potential should have a pregnancy test prior to initiating therapy and must use appropriate contraception during treatment and for nine months following discontinuation of oxaliplatin. Male patients should continue contraception for six months following treatment cessation. Patients should avoid breastfeeding during treatment and for three months following treatment termination."],"specialPopulations":{"Pregnancy":"Can cause fetal harm. Advise pregnant women of the potential risk to the fetus. Effects on the breastfed infant or on milk production are unknown. Because of the potential for serious adverse reactions, advise lactating women not to breastfeed during treatment with ELOXATIN and for at least 2 months after the final dose.","Geriatric use":"No dose adjustment is required in patients 65 years of age and older. However, due to the higher frequency of decreased renal function in the elderly, consider dose reduction in patients with renal impairment.","Paediatric use":"The safety and effectiveness of ELOXATIN in pediatrics have not been established. Safety and efficacy have not been established in pediatric patients.","Renal impairment":"In patients with severe renal impairment (creatinine clearance [CLcr] less than 30 mL/min, calculated by the Cockcroft-Gault equation), reduce the ELOXATIN dose to 65 mg/m2.","Hepatic impairment":"Consider evaluating patients who develop abnormal liver tests or portal hypertension which cannot be explained by liver metastases, for hepatic vascular disorders. Monitor liver function tests at baseline, before each receiving ELOXATIN with fluorouracil/leucovorin and oral anticoagulants."}},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=folfox-7","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:57:01.678029+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:57:07.054598+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:57:01.880867+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=folfox-7","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:57:07.249047+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1230575/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:57:08.300981+00:00"}},"offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"Folfox-7 is a chemotherapy regimen marketed by Pfizer Inc. It targets various molecular targets to treat metastatic colorectal cancer. The mechanism involves a combination of drugs to inhibit cancer cell growth and proliferation. Folfox-7 has shown clinical differentiation in its ability to improve patient outcomes. Its commercial significance is evident in its high revenue of $63.6B. The pipeline developments for folfox-7 are not publicly available.","brandName":"Folfox-7","ecosystem":[],"isGeneric":true,"mechanism":{"target":"DNA replication machinery","novelty":"best-in-class","modality":"small molecule","drugClass":"chemotherapy","explanation":"","oneSentence":"","technicalDetail":"Folfox-7 targets the DNA replication machinery of cancer cells, inhibiting their ability to proliferate. The combination of oxaliplatin, 5-fluorouracil, and leucovorin enhances the efficacy of the treatment. This regimen is effective in treating metastatic colorectal cancer."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:28:37.770Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"7%","annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"","peakSalesEstimate":""},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=folfox-7","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=folfox-7","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":4,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:57:10.053544+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"FOLFOX-4","company":"Not specified","advantage":"Alternative to FOLFOX-7 due to lower toxicity and suitability for patients with high age, comorbidities, or post-surgical complications"},{"name":"FOLFOX","company":"Not specified","advantage":"Alternative to FOLFOX-7 due to its effectiveness in adjuvant chemotherapy for stage III colic cancer"},{"name":"FOLFOX (with splenomegaly)","company":"Not specified","advantage":"Alternative to FOLFOX-7 for patients with stages II-III colorectal cancer and splenomegaly"},{"name":"FOLFOX (with methylation and microsatellite status)","company":"Not specified","advantage":"Alternative to FOLFOX-7 for patients with specific methylation and microsatellite status"}],"genericName":"folfox-7","indications":{"approved":[{"name":"Metastatic colorectal cancer","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00208260","phase":"PHASE2, PHASE3","title":"Intensified Chemotherapy in CRC After Resection of Liver Metastases","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2004-04","conditions":"Colorectal Cancer, Liver Metastases, Chemotherapy","enrollment":124},{"nctId":"NCT06172205","phase":"PHASE3","title":"Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-07-01","conditions":"BCLC Stage C Hepatocellular Carcinoma, Chemotherapy Effect","enrollment":262},{"nctId":"NCT05786924","phase":"PHASE1, PHASE2","title":"Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies","status":"RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2023-04-18","conditions":"Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis","enrollment":554},{"nctId":"NCT03828227","phase":"PHASE3","title":"QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2019-06-14","conditions":"Elderly Patients, Metastatic Colorectal Cancer, Quality of Life","enrollment":49},{"nctId":"NCT02979483","phase":"NA","title":"Management of Symptomatic Advanced Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2016-12-19","conditions":"Pancreas, Management Supportive Care Program","enrollment":110},{"nctId":"NCT03530267","phase":"PHASE2","title":"Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer","status":"COMPLETED","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2018-09-28","conditions":"Colorectal Cancer","enrollment":124},{"nctId":"NCT01606098","phase":"PHASE3","title":"The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer","status":"COMPLETED","sponsor":"Dutch Colorectal Cancer Group","startDate":"2012-07","conditions":"Colon Cancer, Primary Tumour, Rectal Cancer","enrollment":206},{"nctId":"NCT01871571","phase":"PHASE2","title":"Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer","status":"UNKNOWN","sponsor":"University of Southern California","startDate":"2013-08-02","conditions":"Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer","enrollment":17},{"nctId":"NCT00803647","phase":"PHASE2","title":"A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2010-01","conditions":"Metastatic Colorectal Cancer","enrollment":20},{"nctId":"NCT00115765","phase":"PHASE3","title":"PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-06-01","conditions":"Colorectal Cancer","enrollment":1053},{"nctId":"NCT01581307","phase":"PHASE2","title":"Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2012-04","conditions":"Liver Cancer, Pancreatic Cancer","enrollment":9},{"nctId":"NCT01802684","phase":"PHASE2","title":"OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2013-05","conditions":"Unresectable Metastatic Colorectal Cancer","enrollment":49},{"nctId":"NCT00571740","phase":"PHASE2","title":"Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer","status":"WITHDRAWN","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"","conditions":"Colorectal Cancer","enrollment":0},{"nctId":"NCT00729677","phase":"","title":"Delayed Nausea and Vomiting in Patients With Colorectal Cancer Receiving Oxaliplatin","status":"COMPLETED","sponsor":"Beth Israel Medical Center","startDate":"2005-06","conditions":"Colorectal Cancer, Nausea, Vomiting","enrollment":64},{"nctId":"NCT01466569","phase":"PHASE1","title":"An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"AbGenomics B.V Taiwan Branch","startDate":"2011-11","conditions":"Solid Tumor of Epithelial Origin, Gastric Cancer","enrollment":13},{"nctId":"NCT00268398","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Colorectal Cancer and Resectable Metastases","status":"COMPLETED","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2002-07","conditions":"Colorectal Cancer, Metastatic Cancer, Chemotherapy","enrollment":284},{"nctId":"NCT01175291","phase":"PHASE2","title":"FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer","status":"WITHDRAWN","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2010-09","conditions":"Metastatic Colorectal Cancer","enrollment":0},{"nctId":"NCT00643877","phase":"PHASE3","title":"Trial of Preoperative Hepatic and Regional Arterial Chemotherapy (PHRAC) to Prevent Postoperative Liver Metastasis of Colorectal Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2008-12","conditions":"Colorectal Neoplasms","enrollment":600},{"nctId":"NCT00268333","phase":"PHASE2","title":"Combination Chemotherapy and Radiation Therapy in Treating Patients With Recurrent Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2005-08","conditions":"Colorectal Cancer","enrollment":39}],"_emaApprovals":[{"date":"","name":"FOLFOX-7","status":"Authorised","regulator":"EMA"}],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL1230575","pubchemSID":"135264420"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":8,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[{"date":"2024 Jun 27","pmid":"38935163","title":"Prognostic value of tumor regression grade (TRG) after oncological gastrectomy for gastric cancer.","journal":"Langenbeck's archives of surgery"},{"date":"2019","pmid":"31534492","title":"Characteristics and survival of older patients with metastatic pancreatic cancer: a retrospective analysis of the AC Camargo Cancer Center experience.","journal":"Therapeutic advances in medical oncology"},{"date":"2019 Jul-Sep","pmid":"31489288","title":"Adjuvant chemotherapy in stage II-III operated colon cancer patients from a nontrial cohort in a low colon cancer prevalence country with predominant use of modified CAPOX.","journal":"South Asian journal of cancer"},{"date":"2013 Jun 28","pmid":"23558935","title":"Expression of ABCG2 associated with tumor response in metastatic colorectal cancer patients receiving first-line FOLFOX therapy--preliminary evidence.","journal":"The International journal of biological markers"},{"date":"2010 Jan","pmid":"20078613","title":"Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.","journal":"British journal of clinical pharmacology"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":4,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:57:10.053544+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}